… and ipilimumab plus nivolumab in melanoma brain metastases. We report … NIBIT-M2 study,
the first phase III trial comparing these regimens with fotemustine in patients with melanoma …

… phase III, NIBIT-M2 study is randomizing MM patients with brain … of ipilimumab in melanoma
patients with brain metastases, in … -PD-1 mAb nivolumab, the NIBIT-M2 study has been lately …

… Along this line the phase III NIBIT-M2 trial, comparing the … and fotemustine in patients with
advanced melanoma (NIBIT-M1): … Three-year follow-up of advanced melanoma patients who …

… mg/m 2 /day in case no DLTs were observed at 30 mg/m 2 /day… also in the initial six patients
treated at 45 mg/m 2 /day, the … on melanoma cells induced by treatment in our NIBIT-M4 …

… of advanced melanoma. Methods: Patients with unresectable Stage III/IV melanoma
received escalating doses of guadecitabine 30, 45 or 60 mg/m 2 subcutaneously on Days 1…

… escalation, single-center NIBIT-M4 study, enrolled pre-treated or untreated patients with
unresectable Stage III or IV melanoma, to receive guadecitabine 30, 45, or 60 mg/m 2 /day sc on …

… melanoma (MM) patients (pts) with BM for over two decades. The Italian Network for Tumor
Biotherapy (NIBIT… We here report the results of the primary analysis of the NIBIT-M2 study, the …

… The Italian Network for Tumor Biotherapy (NIBIT) … NIBIT-M1 is a phase II, open-label,
single arm study that enrols unresectable stage III or IV cutaneous melanoma pts in seven NIBIT …

… escalation, single-center NIBIT-M4 study, enrolled pre-treated or untreated patients with
unresectable Stage III or IV melanoma, to receive guadecitabine 30, 45, or 60 mg/m 2 /day sc on …

… NIBIT-M2 study provide the longest evidence of the efficacy of ipilimumab plus nivolumab in
melanoma patients … year primary analysis of the NIBIT-M2 study demonstrated that treatment …